Drugs.com - New Drug Approvals

FDA Approves Symvess (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma

DURHAM, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the U.S. Food and Drug...

Feb 9, 2025 - 22:25
 0
FDA Approves Symvess (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
DURHAM, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the U.S. Food and Drug...
Read More

Tags:

Previous Article

FDA Approves Tryngolza (olezarsen) to Reduce Triglycerides in Adults with Famili...

Next Article

FDA Approves Ryoncil (remestemcel-L-rknd) Mesenchymal Stromal Cell Therapy for S...

Related Posts

FDA Approves Ensacove (ensartinib) for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

FDA Approves Ensacove (ensartinib) for ALK-Positive Loc...

Feb 9, 2025  0

FDA Approves Steqeyma (ustekinumab-stba), a Biosimilar to Stelara

FDA Approves Steqeyma (ustekinumab-stba), a Biosimilar ...

Feb 9, 2025  0

FDA Approves Imkeldi (imatinib) Oral Solution for the Treatment of Certain Forms of Leukemia and Other Cancers

FDA Approves Imkeldi (imatinib) Oral Solution for the T...

Feb 9, 2025  0